| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 0.00 | 0.00 |
| Net Income | -50.37 | -41.40 |
| Diluted EPS | -0.15 | -0.19 |
- Net Income YoY
- -21.7%
Key highlights
- Net loss widened to $50.37 million in Q3 2026, a 21.7% increase from the $41.40 million loss in Q3 2025
- Diluted earnings per share improved to -$0.15 compared to -$0.19 in the prior year period
- Total stockholders' equity increased to $392.6 million from $292.5 million at the end of 2025
- Company reaffirmed full-year 2026 cash operating expense guidance of approximately $165 million
- Zero revenue was recorded for the period, consistent with the company's clinical-stage status
How the Period Went
Allogene Therapeutics reported a net loss of $50.37 million for the third quarter of 2026, representing a 21.7% increase compared to the $41.40 million loss recorded in the same period of 2025. As a clinical-stage biotechnology firm, the company generated zero revenue during the quarter, consistent with its status as a developer of pre-commercial therapies. Despite the larger net loss, diluted earnings per share improved to -$0.15 from -$0.19 in the prior year. This movement was primarily influenced by an increased share count following capital-raising activities, which effectively distributed the total loss across a larger volume of outstanding common stock.
Margins and Profitability
Operating expenses continue to drive the company's financial results as Allogene advances its AlloCAR T platform. While net losses have fluctuated—rising from $42.7 million in Q2 2026 to $50.37 million this quarter—the company has focused on liquidity management. Through a combination of a public offering and at-the-market sales, Allogene grew its total stockholders' equity to $392.6 million, up from $292.5 million at the end of 2025. Management has reaffirmed guidance for full-year 2026 GAAP operating expenses of approximately $225 million, noting that current capital reserves are expected to support operations into 2029.
Business Overview
Based in the United States, Allogene Therapeutics is a biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell therapies for cancer and autoimmune diseases. Unlike autologous treatments that use a patient's own cells, Allogene’s AlloCAR T™ candidates are designed to be available off-the-shelf, potentially reducing treatment wait times. The company's current focus is on advancing its lead programs through clinical milestones, including the pivotal Phase 2 ALPHA3 trial. Because its products remain in the investigational stage, the company maintains no commercial backlog and relies on equity markets and partnerships for funding.
Financial Context
The stock has faced significant headwinds, with a price decline of 42.63% over the last quarter, closing at $1.09. This market valuation of $376.6 million currently trades slightly below the company's book value of $392.6 million in equity. Technical indicators place the stock in a near-oversold position with an RSI of 31.3. The widening Q3 loss follows a period of stable quarterly burn, as losses in the first two quarters of 2026 were $42.6 million and $42.7 million, respectively. Investors are currently monitoring the company's ability to maintain its multi-year cash runway while awaiting clinical data readouts.
Down 26.0% since our story on 6 Nov: $1.09 when we broke it → $0.81 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $1.30 |
|---|---|
| 20 Oct | $1.33 |
| 21 Oct | $1.33 |
| 22 Oct | $1.25 |
| 23 Oct | $1.25 |
| 26 Oct | $1.21 |
| 27 Oct | $1.23 |
| 28 Oct | $1.30 |
| 29 Oct | $1.25 |
| 30 Oct | $1.18 |
| 2 Nov | $1.09 |
| 3 Nov | $1.12 |
| 4 Nov | $1.19 |
| 5 Nov | $1.09 |
| 6 Nov | $1.04 |
| 9 Nov | $1.06 |
| 10 Nov | $0.93 |
| 11 Nov | $0.90 |
| 12 Nov | $0.83 |
| 13 Nov | $0.84 |
| 16 Nov | $0.81 |
Industry Landscape
- Upcoming presentation of preliminary Phase 1 clinical data for ALLO-329 across three dose levels on November 9, 2026
- Strategic shift toward autoimmune applications reflecting a broader trend in the CAR T sector
- Planned interim event-free survival analysis for the pivotal Phase 2 ALPHA3 trial anticipated in mid-2027
- Increased sector competition from both autologous CAR T providers and emerging allogeneic developers
- Peer valuations remain volatile as clinical-stage biotechs face high capital costs and rigorous regulatory pathways
| Date | Announcement | Amount |
|---|---|---|
| 05 Nov 2026 | Q3 2026 net lossSource: ir.allogene.com | $50.4 Million |
| 12 Aug 2026 | Q2 2026 net lossSource: allogene.gcs-web.com | $42.7 Million |
| 13 May 2026 | Q1 2026 net lossSource: ir.allogene.com | $42.6 Million |
| 12 Mar 2026 | Q4 2025 net lossSource: ir.allogene.com | $38.8 Million |
| 06 Nov 2025 | Q3 2025 net lossSource: ir.allogene.com | $41.4 Million |
| 13 Aug 2025 | Q2 2025 net lossSource: ir.allogene.com | $50.9 Million |
Management commentary
“The company strengthened its balance sheet through a public offering and ATM sales, ending the period with $392.6 million in total stockholders' equity compared to $292.5 million at the end of 2025.”
| Share price | $1.09 |
|---|---|
| Market cap | $377M |
| 1-month price change | -25.34% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Quarterly report filed with the SEC by Allogene Therapeutics, Inc. for the period ending September 30, 2026.
Track Allogene Therapeutics, Inc. live
Get the next Allogene Therapeutics, Inc. SEC filing seconds after it lands.



